Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 296Recruiting 124Unknown 123Active not recruiting 59Terminated 47Not yet recruiting 29Withdrawn 15Enrolling by invitation 5Approved for marketing 2Suspended 1No longer available 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 46Breast Neoplasms 46Colorectal Neoplasms 27Prostatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 20Glioblastoma 19Melanoma 17Lung Neoplasms 17Pancreatic Neoplasms 16Neoplasm Metastasis 16Glioma 14Stomach Neoplasms 13Ovarian Neoplasms 13Brain Neoplasms 13Carcinoma, Hepatocellular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Triple Negative Breast Neoplasms 10Multiple Myeloma 10Head and Neck Neoplasms 10Carcinoma, Renal Cell 10Lymphoma 9Uterine Cervical Neoplasms 7Sarcoma 7Rectal Neoplasms 7Leukemia 7Hematologic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7

Interventions

lenvatinib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Thyroid Neoplasms × Clear all
NCT03139747 2021-10-15

UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

Thomas Jefferson University

Phase 2 Suspended
5 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡